Revance (RVNC) Announces Positive Topline Phase 2 Data Supporting Advancement of DaxibotulinumtoxinA for Injection for the Treatment of Upper Limb Spasticity

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. HOOD
9. MU
10. IBM

Go back to Revance (RVNC) Announces Positive Topline Phase 2 Data Supporting Advancement of DaxibotulinumtoxinA for Injection for the Treatment of Upper Limb Spasticity

Revance Therapeutics (RVNC) Reports In-Line Q4 EPS, Revenues Beat

February 22, 2021 4:41 PM EST

Revance Therapeutics (NASDAQ: RVNC) reported Q4 EPS of ($1.24), in-line with the analyst estimate of ($1.24). Revenue for the quarter came in at $11.13 million versus the consensus estimate of $8.78 million.

Fourth quarter and full year 2020 total product and service revenue of $10.2 million and $13.3 million, respectivelyFirst full quarter of RHA® Collection of dermal fillers revenue of $10.0 millionExited 2020 with over $200 million in annualized HintMD processing volumeCash, cash equivalents and short-term investments balance of $436.5 million at... More